eligibility_summary
Adults with R/R MM, measurable disease, ECOG 0–1, >3‑mo survival, refractory to ≥1 PI, ≥1 IMiD and a CD38 mAb, PD during/≤12 mo after last therapy, contraception required. Exclude: recent cancers, unresolved ≥G2 toxicity, recent major surgery/thrombosis, uncontrolled CV, infection, hepatic/renal/lung disease, diabetes, epilepsy, immunodeficiency, AL amyloidosis/PCL/WM/POEMS/CNS MM, prior BCMA, allo‑HSCT, CAR‑T/NK, recent ASCT/tx/live vaccine, severe allergies.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05646758 tests TQB2934, an IgG1 bispecific antibody (drug) that binds CD3 on T cells and BCMA (TNFRSF17) on malignant plasma cells in multiple myeloma. Mechanism: it bridges T cells to BCMA+ cells, triggering CD3/TCR signaling, immune synapse formation, and T-cell activation. Activated T cells release perforin and granzymes and secrete cytotoxic cytokines to kill BCMA-expressing tumor cells. Targets: CD3 on T lymphocytes (activating T-cell effector pathways) and BCMA on plasma/myeloma cells (depleting BCMA+ B-lineage cells). Administration is IV with dose escalation, frequency tapers with response.